Advertisement

Drug Safety

, Volume 27, Issue 6, pp 411–420 | Cite as

Upper Gastrointestinal Bleeding Associated with the Use of NSAIDs

Newer Versus Older Agents
  • Joan-Ramon LaporteEmail author
  • Luisa Ibanez
  • Xavier Vidal
  • Lourdes Vendrell
  • Roberto Leone
Original Research Article

Abstract

Aim: The relative gastrointestinal toxicity of NSAIDs in normal clinical practice is unknown. The aim of this study was to estimate the risk of upper gastrointestinal bleeding associated with NSAIDs and analgesics, with special emphasis on those agents that have been introduced in recent years.

Design: Multicentre case-control study.

Patients: All incident community cases of upper gastrointestinal bleeding from a gastric or duodenal lesion in patients aged >18 years of age (4309 cases). After secondary exclusions, 2813 cases and 7193 matched controls were included in the analysis.

Setting: Eighteen hospitals in Spain and Italy with a total study experience of 10 734 897 person-years.

Main Outcome Measure: Odds ratios of upper gastrointestinal bleeding for each drug, with adjustment for potential confounders. For each individual drug the reference category was defined as those not exposed to the drug.

Results: The incidence of upper gastrointestinal bleeding was 401.4 per million inhabitants aged >18 years. Thirty-eight percent of cases were attributable to NSAIDs. Individual risks for each NSAID were dose dependent. Ketorolac was associated with the highest risk estimate (24.7; 95% CI 8.0, 77.0). For newer NSAIDs, the risks were as follows: aceclofenac 1.4 (95% CI 0.6, 3.3), celecoxib 0.3 (95% CI 0.03, 4.1), dexketoprofen 4.9 (95% CI 1.7, 13.9), meloxicam 5.7 (95% CI 2.2, 15.0), nimesulide 3.2 (95% CI 1.9, 5.6) and rofecoxib 7.2 (95% CI 2.3, 23.0). The risk was significantly increased in patients with a history of peptic ulcer and/or upper gastrointestinal bleeding, and in those taking antiplatelet drugs.

Conclusions: NSAID-induced upper gastrointestinal bleeding is a common cause of hospital admission. Apart from the patient’s history of peptic ulcer, its risk depends on the particular drug and its dose, and on concomitant treatments. Our results do not confirm that greater selectivity for COX-2 confers less risk of upper gastrointestinal bleeding.

Keywords

Peptic Ulcer Celecoxib Naproxen Gastrointestinal Bleeding Piroxicam 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

The Spanish-Italian Collaborative Group for the Epidemiology of Upper Gastrointestinal Bleeding consists of the following individuals

Central Management and Coordinating Group: L Ibáñez, X Vidal, L Vendrell, J-R Laporte; Fundació Institut Català de Farmacologia, Barcelona, Spain.

Coordinating team in Italy: R Leone, U Moretti, A Conforti; Servizio di Farmacologia Medica, Università di Verona, Verona, Italy.

Investigators: E Vargas, M Ateinza, Hospital Clínico San Carlos, Madrid, Spain; J Torelló, O Belda, Hospital Virgen del Rocío, Sevilla, Spain; A Obrador, J Gayà, Hospital Son Dureta, Palma de Mallorca, Spain; F Guarner, JR Armengol, JR Malagelada, Hospital Universitari Vall d’Hebron, Barcelona, Spain; C Aguirre, J Cabriada, Hospital de Galdakao, Bizkaia, Spain; X Carné, F Feu, Hospital Clínic, Barcelona, Spain; T Caro-Patón, ML Goyeneche, Hospital Río Hortega, Valladolid, Spain; A Carvajal, Instituto de Farmacoepidemiología de Castilla-León; L del Olmo, Hospital Clínico, Valladolid, Spain; P Salvàt, J Costa, Hospital Germans Trias i Pujol, Badalona, Spain; J Balanzó, C Villanueva, Hospital Santa Creu i Sant Pau, Barcelona, Spain; G Angelini, A Castagnini, Policlinico GB Rossi, Verona, Italy; C Cordiano, G Guglielmi, Ospedale Civile Maggiore, Verona, Italy; S Loperfido, Ospedale Cà Foncello, Treviso, Italy; D Bernardini, L Milan, Presidio Ospedaliero S Bortolo, Vicenza, Italy; S Adamo, GM Bulighin, Ospedale Magalini, Villafranca di Verona, Italy; M Azzurro, Ospedale Orlandi, Bussolengo, Italy; F Chilovi, L Piazzi, Ospedale Generale Regionale, Bolzano, Italy; R Musola, M Azzini, Presidio Ospedaliero, Legnago, Italy.

Quality control and data entry in Spain: L Vendrell, X Barroso, Fundació Institut Català de Farmacologia, Barcelona, Spain.

Quality control and data entry in Italy: S Bisi, T Camerlengo, Servizio di Farmacologia Medica, Università di Verona, Verona, Italy.

Statistical support and analysis: X Vidal, Fundacio Institut Català de Farmacologia, Barcelona, Spain.

Data collection: A Terleira, S Fernández, I Navarro, Hospital Clinico San Carlos, Madrid, Spain; A Mengíbar, Hospital Virgen del Rocío, Sevilla, Spain; R Soto, Hospital Son Dureta, Palma de Mallorca, Spain; MJ de las Heras, Hospital Universitari Vall d’Hebron, Barcelona, Spain; M García, A Ajuria, Hospital de Galdakao, Bizkaia; G Santana, Hospital Clínic, Barcelona, Spain; A García, Hospital Río Hortega, Valladolid, Spain; N Alonso, Hospital Clínico, Valladolid, Spain; E Roldán, Hospital Germans Trias i Pujol, Badalona, Spain; ML Gálvez, Hospital Santa Creu i Sant Pau, Barcelona, Spain; B Rapanà, Policlinico GB Rossi, Verona; M Casoni, Ospedale Civile Maggiore, Verona, Italy; E Heras, D Nardi, Ospedale Cà Foncello, Treviso, Italy; S Gasparotto, Presidio Ospedaliero San Bortolo, Vicenza, Italy; G Franzon, Ospedale Magalini, Villafranca di Verona, Italy, and Ospedale Orlandi, Bussolengo, Italy; T Grasso, Ospedale Generale Regionale, Bolzano, Italy; R Pasqualini, Presidio Ospedaliero, Legnago, Italy.

Funding

In Spain, Almirall Prodesfarma, Aventis, Bayer, Boehringer Ingelheim, Ferrer Internacional, J Uriach y Cía, Knoll, Laboratorios del Dr Esteve, Lácer, Menarini, Merck Sharp and Dohme, Monsanto España, Novartis, Roche, Sanofi- Synthélabo, and Vita-Invest.

In Italy, Boehringer Ingelheim, Helsinn, and Roche.

The design, conduct, analysis and interpretation of the study were totally independent from the sponsoring companies. These were approached for potential funding after approval of the protocol by the study group.

Conflict of interest statement: The Fundació Institut Català de Farmacologia (FICF) and the Servizio di Farmacologia Medica (SFMV) have research contracts with the pharmaceutical companies supporting the present study. Personnel at these institutions do not receive any premium related to these contracts.

References

  1. 1.
    Laporte JR, Carné X, Vidal X, et al. Upper gastrointestinal bleeding in relation to previous use of analgesics and nonsteroidal anti-inflammatory drugs. Lancet 1991; 337: 85–9PubMedCrossRefGoogle Scholar
  2. 2.
    Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343: 1075–8PubMedCrossRefGoogle Scholar
  3. 3.
    Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834–9PubMedCrossRefGoogle Scholar
  4. 4.
    Henry D, Lim LL-Y, García Rodríguez LA, et al. Variability in risk of gastrointestinal complications with individual nonsteroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563–6PubMedCrossRefGoogle Scholar
  5. 5.
    Lewis SC, Langman MJS, Laporte J-R, et al. Dose-response relationships between individual non-aspirin non-steroidal anti-inflammatory drugs (NANSAIDs) and serious upper gastrointestinal bleeding: a meta-analysis based on individual patient data. Br J Clin Pharmacol 2002; 54: 320–34PubMedCrossRefGoogle Scholar
  6. 6.
    Hernández-Díaz S, García-Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093–9PubMedCrossRefGoogle Scholar
  7. 7.
    García-Rodríguez LA, Hernández-Díaz S. Relative risk of upper gastrointestinal complications among users of paracetamol and nonsteroidal anti-inflammatory drugs. Epidemiology 2001; 12: 570–6PubMedCrossRefGoogle Scholar
  8. 8.
    Mellemkjaer L, Blot WJ, Sorensen HT, et al. Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark. Br J Clin Pharmacol 2002; 53: 173–81PubMedCrossRefGoogle Scholar
  9. 9.
    Bruzzi P, Green SB, Byar DP, et al. Estimating the population attributable risk for multiple risk factors using case-control data. Am J Epidemiol 1985; 122: 904–14PubMedGoogle Scholar
  10. 10.
    Traversa G, Walker AM, Ippolito FM, et al. Gastroduodenal toxicity of different nonsteroidal antiinflammatory drugs. Epidemiology 1995; 6: 49–54PubMedCrossRefGoogle Scholar
  11. 11.
    García-Rodríguez LA, Cattaruzzi C, Troncon MG, et al. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158: 33–9PubMedCrossRefGoogle Scholar
  12. 12.
    Menniti-Ippolito F, Maggini M, Raschetti R, et al. Ketorolac use in outpatients and gastrointestinal hospitalization: a comparison with other non-steroidal anti-inflammatory drugs in Italy. Eur J Clin Pharmacol 1998; 54: 393–7PubMedCrossRefGoogle Scholar
  13. 13.
    Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from non-aspirin nonsteroidal anti-inflammatory drugs. Gastroenterology 1993; 105: 1078–88PubMedGoogle Scholar
  14. 14.
    Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. N Engl J Med 1974; 290: 1158–62PubMedCrossRefGoogle Scholar
  15. 15.
    Kaufman DW, Kelly JP, Sheehan JE, et al. Nonsteroidal antiinflammatory drug use in relation to major upper gastrointestinal bleeding. Clin Pharmacol Ther 1993; 53: 485–94PubMedCrossRefGoogle Scholar
  16. 16.
    Bombardier C, Laine L, Reicin A, et al. for the VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343: 1520–8PubMedCrossRefGoogle Scholar
  17. 17.
    Mamdani M, Rochon PA, Juurlink DN, et al. Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 2002; 325: 624–9PubMedCrossRefGoogle Scholar
  18. 18.
    Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase- 2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A 1999; 96: 7563–8PubMedCrossRefGoogle Scholar
  19. 19.
    Kulkarni SK, Jain NK, Singh A. Cyclooxygenase isoenzymes and newer therapeutic potential for selective COX-2 inhibitors. Methods Find Exp Clin Pharmacol 2000; 22: 291–8PubMedCrossRefGoogle Scholar
  20. 20.
    Patrignani P, Panara MR, Sciulli MG, et al. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 1997; 48: 623–31PubMedGoogle Scholar
  21. 21.
    Feldman M, McMahon AT. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional non-steroidal anti-inflammatory drugs, with less gastrointestinal toxicity? Ann Intern Med 2000; 132: 134–43PubMedGoogle Scholar
  22. 22.
    Llorente Melero MJ, Tenías Burillo JM, Zaragoza Marcet A. Comparative incidence of upper gastrointestinal bleeding associated with individual non-steroidal anti-inflammatory drugs [in Spanish]. Rev Esp Enferm Dig 2002; 94: 7–12PubMedGoogle Scholar
  23. 23.
    Peris F, Bird HA, Serni U, et al. Treatment compliance and safety of aceclofenac versus standard NSAIDs in patients with common arthritic disorders: a meta-analysis. Eur J Rheumatol Inflamm 1996; 16: 37–45Google Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  • Joan-Ramon Laporte
    • 1
    • 2
    Email author
  • Luisa Ibanez
    • 1
    • 2
  • Xavier Vidal
    • 1
    • 2
  • Lourdes Vendrell
    • 2
  • Roberto Leone
    • 3
  1. 1.Department of Pharmacology, Therapeutics and ToxicologyUniversitat Autonoma de Barcelona, Fundacio Institut Catala de Farmacologia, Hospital Universitari Vall d’Hebron, Universitat Autoonoma de BarcelonaBarcelonaSpain
  2. 2.Clinical Pharmacology ServiceHospital Universitari Vall d’HebronCataloniaSpain
  3. 3.Servizio di Farmacologia MedicaUniversita di VeronaVeronaItaly

Personalised recommendations